228
Z. Xu et al.
LETTER
Hulme, C. Tetrahedron Lett. 2012, 53, 1998. (d) Shaw, A.
Y.; McLaren, J. A.; Nichol, G. S.; Hulme, C. Tetrahedron
Lett. 2012, 53, 2592. (e) Ayaz, M.; Dietrich, J.; Hulme, C.
Tetrahedron Lett. 2011, 52, 4821. (f) Shaw, A. Y.; Medda,
F.; Hulme, C. Tetrahedron Lett. 2012, 53, 1313.
Specifically, two isonitriles, two diamines, and two α-
amino acids were employed with final products obtained
in high overall yields (45–80%). Surprisingly, N-Boc 1,2-
phenylenediamine was found to readily participate in the
Ugi reaction, yet failed to garner the fully constrained tri-
cyclic 11.
(8) For a review, see: Banfi, L.; Riva, R.; Basso, A. Synlett 2010,
23.
(9) Marcaccini, S.; Torroba, T. Nat. Protoc. 2007, 2, 632.
(10) (a) Wang, W.; Dömling, A. J. Comb. Chem. 2009, 11, 403.
(b) Westermann, B.; Neuhaus, C. Angew. Chem. Int. Ed.
2005, 44, 4077.
Conversely, tert-butyl[2-(aminomethyl)phenyl]carbamate
4 (n = 1) readily afforded the 4,6-dihydropyrazinoquinaz-
olinone scaffold 11a–c, in analogy to observations seen
for formation of 1a and 1d, and N-Boc-ethylenediamine
was successfully employed to give 11d and 11e. In sum-
mary, we have herein reported several one-pot, two-step
routes to four scaffolds derived from an Ugi condensation,
followed by either two of three ring-closing events. The
initial Ugi condensation takes place under mild condi-
tions, and subsequent acid-triggered cyclizations afford
the arrays of nitrogen-containing polycyclic frameworks
presented herein. Due to the facile nature of the method-
ology, it is expected to be a useful tool amenable to paral-
lel synthesis and could become a method of choice for the
preparation of the polycyclic moieties described herein.
(11) General Procedure for the Preparation of Compounds
1a–g and 11a–e, Exemplified by Compound 1c
tert-Butyl (2-aminophenyl)carbamate (1 equiv, 1.0 mmol,
208 mg) and ethyl glyoxylate (1.5 equiv, 1.5 mmol, 361 μL
of a 50% solution in toluene) were dissolved in TFE (5 mL).
After 10 min, N-Boc-glycine (1 equiv, 1.0 mmol, 175 mg)
and 6-isocyano-2,3-dihydrobenzo[b][1,4]dioxane (1 equiv,
1.0 mmol, 161 mg) were added to the reaction mixture,
which was stirred overnight at r.t. The reaction was
monitored by LC–MS and TLC. Upon completion, the
solvent was removed in vacuo and the crude material
dissolved in 10% TFA–DCE (3.0 mL), with subsequent
irradiation at 120 °C for 10 min. After the vial was cooled to
r.t., the mixture was diluted with EtOAc (50 mL), and the
organic layer was washed with sat. NaHCO3 (20 × 2 mL) and
brine. The organic phase was dried over MgSO4, evaporated
in vacuo, and the crude material was purified by flash
chromatography (MeOH–EtOAc 0–10%) using an ISCO
purification system to afford N-{2,3-dihydrobenzo-
[b][1,4]dioxan-6-yl}-3-oxo-1,2,3,4-tetrahydrobenzo-
[4,5]imidazo[1,2-a]pyrazine-4-carboxamide (1c) as a white
solid (197 mg, 54% yield). 1H NMR (400 MHz, DMSO-d6):
δ = 10.89 (s, 1 H), 8.94–8.78 (m, 1 H), 7.68–7.58 (m, 1 H),
7.40 (dd, J = 6.2, 2.9 Hz, 1 H), 7.30–7.15 (m, 3 H), 7.01 (dd,
J = 8.7, 2.3 Hz, 1 H), 6.81 (d, J = 8.7 Hz, 1 H), 5.74 (s, 1 H),
4.88–4.59 (m, 2 H), 4.19 (s, 4 H). 13C NMR (100 MHz,
DMSO-d6): δ = 163.1, 162.5, 146.0, 143.2, 143.0, 140.1,
132.8, 131.5, 122.6, 122.3, 118.9, 117.0, 112.6, 109.5,
108.4, 64.1, 63.9, 60.6. MS: m/z = 365 [M + H]+. ESI-
HRMS: m/z calcd for C19H17N4O4 [M + H]+: 365.1244;
found: 365.1242.
(12) For examples of the biological profiles displayed by the
benzimidazole core, see: (a) Zarrinmayeh, H.; Nunes, A. M.;
Ornstein, P. L.; Zimmerman, D. M.; Arnold, M. B.; Schober,
D. A.; Gackenheimer, S. L.; Bruns, R. F.; Hipskind, P. A.;
Britton, T. C.; Cantrell, B. E.; Gehlert, D. R. J. Med. Chem.
1998, 41, 2709. (b) He, Y.; Yang, J.; Wu, B.; Risen, L.;
Swayze, E. E. Bioorg. Med. Chem. Lett. 2004, 14, 1217.
(c) Horn, J. Clin. Therap. 2000, 22, 266. (d) Prichard, M. N.;
Frederick, S. L.; Daily, S.; Borysko, K. Z.; Townsend, L. B.;
Drach, J. C.; Kern, E. R. Antimicrob. Agents Chemother.
2011, 55, 2442. (e) Li, Y.; Tan, C.; Gao, C.; Zhang, C.;
Luan, X.; Chen, X.; Liu, H.; Chen, Y.; Jiang, Y. Bioorg.
Med. Chem. 2011, 19, 4529.
Acknowledgment
Financial support from the National Institutes of Health (Grant
P41GM086190) is gratefully acknowledged. We also thank Dr.
Federico Medda and Dr. David Bishop for proofreading and copy-
editing.
References and Notes
(1) For recent examples, see: (a) Lian, X.; Ma, S. Chem. Eur. J.
2010, 16, 7960. (b) Medley, J. W.; Movassaghi, M. Angew.
Chem. Int. Ed. 2012, 51, 4572. (c) Murata, T.; Murai, M.;
Ikeda, Y.; Miki, K.; Ohe, K. Org. Lett. 2012, 14, 2296.
(d) Chiou, W. H.; Lin, Y. H.; Chen, G. T.; Gao, Y. K.; Tseng,
Y. C.; Kao, C. L.; Tsai, J. C. Chem. Commun. 2011, 47,
3562. (e) Gembus, V.; Janvier, S.; Lecouvé, J. P.; Vaysse-
Ludot, L.; Brièrea, J. F.; Levacher, V. Org. Biomol. Chem.
2012, 10, 2003.
(2) For reviews, see: (a) Nicolaou, K. C.; Chen, J. S. Chem. Soc.
Rev. 2009, 38, 2993. (b) Malacria, M. Chem. Rev. 1996, 96,
289.
(3) (a) Santra, S.; Andreana, P. R. Angew. Chem. Int. Ed. 2011,
50, 9418. (b) Ribelin, T. P.; Judd, A. S.; Akritopoulou-
Zanze, I.; Henry, R. F.; Cross, J. L.; Whittern, D. N.; Djuric,
S. W. Org. Lett. 2007, 24, 5119. (c) Riva, R.; Banfi, L.;
Basso, A.; Cerulli, V.; Guanti, G.; Pani, M. J. Org. Chem.
2010, 75, 5134.
(4) (a) De Moliner, F.; Hulme, C. Org. Lett. 2012, 14, 1354.
(b) Xu, Z.; De Moliner, F.; Cappelli, A. P.; Hulme, C.
Angew. Chem. Int. Ed. 2012, 51, 8037.
(13) Dömling, A.; Huang, Y. Synthesis 2010, 2859; and
references cited therein.
(5) Ugi, I.; Steinbruckner, C. Angew. Chem. 1960, 72, 267.
(6) (a) Nixey, T.; Kelly, M.; Hulme, C. Tetrahedron Lett. 2000,
41, 8729. (b) Nixey, T.; Kelly, M.; Semin, D.; Hulme, C.
Tetrahedron Lett. 2002, 43, 3681. (c) Hulme, C.; Bienaymé,
H.; Nixey, T.; Chenera, B.; Jones, W.; Tempest, P.; Smith,
A. Methods Enzymol. 2003, 369, 469. (d) Hulme, C.;
Chappeta, S.; Dietrich, J. Tetrahedron Lett. 2009, 50, 4054.
(7) (a) Dietrich, J.; Kaiser, C.; Meurice, N.; Hulme, C.
Tetrahedron Lett. 2010, 51, 3951. (b) Gunawan, S.; Ayaz,
M.; De Moliner, F.; Frett, B.; Kaiser, C.; Patrick, N.; Hulme,
C. Tetrahedron 2012, 68, 5606. (c) Shaw, A. Y.; Xu, Z.;
(14) Shiozaki, M.; Maeda, K.; Miura, T.; Kotoku, M.; Yamasaki,
T.; Matsuda, I.; Aoki, K.; Yasue, K.; Imai, H.; Ubukata, M.;
Suma, A.; Yokota, M.; Hotta, T.; Tanaka, M.; Hase, Y.;
Haas, J.; Fryer, A. M.; Laird, E. R.; Littmann, N. M.;
Andrews, S. W.; Josey, J. A.; Mimura, T.; Shinozaki, Y.;
Yoshiuchi, H.; Inaba, T. J. Med. Chem. 2011, 54, 2839.
(15) (a) Xu, Z.; Shaw, A. Y.; Nichol, G. S.; Cappelli, A. P.;
Hulme, C. Mol. Diversity 2012, 16, 607. (b) Xu, Z.; Ayaz,
M.; Cappelli, A. P.; Hulme, C. ACS Comb. Sci. 2012, 14,
460.
Synlett 2014, 25, 225–228
© Georg Thieme Verlag Stuttgart · New York